DiscoverThe Lancet Respiratory Medicine in conversation withSergio Harari on the treatment of lymphangioleiomyomatosis (LAM)
Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)

Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)

Update: 2024-10-25
Share

Description

Professor Sergio Harari joins us to discuss the results of a phase 2 clinical trial evaluating activity and safety of nintedanib in people with lymphangioleiomyomatosis (LAM).

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)

Sergio Harari on the treatment of lymphangioleiomyomatosis (LAM)

The Lancet Group